Genome-wide analysis of androgen receptor binding sites in prostate cancer cells

Cheng,Yue; Yu,Pan; Duan,Xiuzhi; Liu,Chunhua; Xu,Siqi; Chen,Yuhua; Tan,Yunnian; Qiang,Yun; Shen,Junfang; Tao,Zhihua

doi:10.3892/etm.2015.2406

Genome-wide analysis of androgen receptor binding sites in prostate cancer cells

Authors:
- Yue Cheng
- Pan Yu
- Xiuzhi Duan
- Chunhua Liu
- Siqi Xu
- Yuhua Chen
- Yunnian Tan
- Yun Qiang
- Junfang Shen
- Zhihua Tao
View Affiliations

Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: April 3, 2015 https://doi.org/10.3892/etm.2015.2406
Pages: 2319-2324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transformation of prostate cancer from an androgen-dependent state to an androgen‑independent state is a lethal progression. Alterations in transcriptional programs are the basis of prostate cancer deterioration. The androgen receptor (AR), a member of the nuclear hormone receptor superfamily, mediates prostate cancer progression by functioning primarily through the ligand‑activated transcription of target genes. Therefore, a detailed map of AR‑regulated genes and AR genomic binding sites is required for hormone‑naive and castration‑resistant prostate cancer. Through the use of chromatin immunoprecipitation in combination with direct sequencing, 4,143 AR binding sites were defined in the LNCaP androgen‑sensitive prostate cancer cell line. Using the same method, 2,380 AR binding regions were identified in the LNCaP‑AI long‑term androgen‑deprived cell line. Approximately 8.5% (354/4,143) of the binding regions were mapped to within 2 kb of the transcription start site (TSS) in the LNCaP cells, while ~12.6% (299/2,380) were mapped to within 2 kb of the TSS in the LNCaP‑AI cells. In total, the study mapped 2,796 genes in LNCaP cells and 1,854 genes in LNCaP‑AI cells. The cell lines shared 789 mutual genes. In addition, gene ontology (GO) analysis of the genes revealed that there was a notable overlap between the GO terms in the LNCaP cells and LNCaP‑AI cells. However, GO terms within the biological process domain that were only observed in the LNCaP‑AI cells included the reproduction process, death, immune system process, multi‑organism process, pigmentation and viral reproduction. The major genes in the different GO terms were TNFAIP8, RTN4, APP and SYNE1. Through analyzing the AR binding sites in the two cell types, the present study aimed to map potential AR‑regulated genes, identify their associated transcription factors and provide a new perspective on the biological processes in the development of prostate cancer. The results provided a valuable data set that furthered the understanding of the genome‑wide analysis of AR binding sites in prostate cancer cells, which may be exploited for the development of novel prostate cancer therapeutic strategies.

View Figures

View References

1	Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 10:209–216. 2003. View Article : Google Scholar : PubMed/NCBI
2	Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490. 2004. View Article : Google Scholar : PubMed/NCBI
3	Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 15:2928–2938. 1997.PubMed/NCBI
4	Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hu R, Dunn TA, Wei S, et al: Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zeng R, Liu Z, Sun Y and Xu C: Differential expression and function of AR isoforms in prostate cancer. Oncol Rep. 27:492–498. 2012.PubMed/NCBI
7	Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
8	Richter E, Srivastava S and Dobi A: Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis. 10:114–118. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang Q, Li W, Zhang Y, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wang Q, Li W, Liu XS, et al: A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell. 27:380–392. 2007. View Article : Google Scholar : PubMed/NCBI
11	Yu J, Yu J, Mani RS, et al: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 17:443–454. 2010. View Article : Google Scholar : PubMed/NCBI
12	Jia L, Berman BP, Jariwala U, et al: Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One. 3:e36452008. View Article : Google Scholar : PubMed/NCBI
13	Xu G, Wu J, Zhou L, et al: Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS One. 5:e155192010. View Article : Google Scholar : PubMed/NCBI
14	Tewari AK, Yardimci GG, Shibata Y, et al: Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol. 13:R882012. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Liu T, Meyer CA, et al: Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9:R1372008. View Article : Google Scholar : PubMed/NCBI
16	Bailey TL and Elkan C: Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol. 2:28–36. 1994.PubMed/NCBI
17	Ma W, Noble WS and Bailey TL: Motif-based analysis of large nucleotide data sets using MEME-ChIP. Nat Protoc. 9:1428–1450. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ashburner M, Ball CA, Blake JA, et al: The Gene Ontology Consortium: Gene ontology: tool for the unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
19	Tomlins SA, Mehra R, Rhodes DR, et al: Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 39:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
20	Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM and Isaacs JT: Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate. 70:90–99. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA and Liao S: Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate. 65:287–298. 2005. View Article : Google Scholar : PubMed/NCBI
22	Attard G, Richards J and de Bono JS: New strategies in metastatic prostate cancer: Targeting the androgen receptor signaling pathway. Clin Cancer Res. 17:1649–1657. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lupien M, Eeckhoute J, Meyer CA, et al: FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 132:958–970. 2008. View Article : Google Scholar : PubMed/NCBI
24	Zinzen RP, Girardot C, Gagneur J, Braun M and Furlong EE: Combinatorial binding predicts spatio-temporal cis-regulatory activity. Nature. 462:65–70. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liu T, Gao H, Yang M, Zhao T, Liu Y and Lou G: Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. Tumour Biol. 35:5805–5814. 2014. View Article : Google Scholar : PubMed/NCBI
26	Liu T, Xia B, Lu Y, Xu Y and Lou G: TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction. Hum Pathol. 45:1251–1257. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhang C, Kallakury BV, Ross JS, et al: The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer. 133:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
28	Chase D, McLauchlan G, Eckersall PD, Pratschke J, Parkin T and Pratschke K: Acute phase protein levels in dogs with mast cell tumours and sarcomas. Vet Rec. 170:6482012. View Article : Google Scholar : PubMed/NCBI
29	Papadia C, Louwagie J, Del Rio P, et al: FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia. Inflamm Bowel Dis. 20:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
30	Shi S, Zhou B, Wang Y, et al: Genetic variation in RTN4 3′-UTR and susceptibility to cervical squamous cell carcinoma. DNA Cell Biol. 31:1088–1094. 2012. View Article : Google Scholar : PubMed/NCBI